Screening for colorectal cancer in a high-risk population. Results of a mathematical model
- PMID: 3102307
- DOI: 10.1016/0016-5085(87)90018-7
Screening for colorectal cancer in a high-risk population. Results of a mathematical model
Abstract
A mathematical model was used to estimate the cost-effectiveness of colorectal cancer screening strategies for people who are at high risk because of a first-degree relative with colorectal cancer. The model uses indirect evidence about such factors as cancer incidence, sensitivity and specificity of different tests, and treatment effectiveness. The analysis indicates that for screening people over 40 yr old an annual fecal occult blood test may reduce colorectal cancer mortality by about one-third, either colonoscopy or barium enema may reduce mortality by approximately 85%, a 3-5-yr frequency for endoscopies or barium enemas preserves 70%-90% of the effectiveness of an annual frequency, and beginning screening at age 50 reduces effectiveness by 5%-10%. Although both barium enemas and colonoscopies appear to be effective in reducing mortality, the lower cost of the barium enema makes it a more cost-effective strategy. All of these estimates depend on the baseline estimates of each of the factors incorporated in the model; the conclusions are most sensitive to assumptions about the natural history of adenomatous polyps, the bleeding of adenomas and presymptomatic cancers, and the sensitivity of the fecal occult blood test. Recommendations about colorectal cancer screening must also consider factors such as discomfort, inconvenience, and the availability of various technologies.
Similar articles
-
Cost-effectiveness of colonoscopy in screening for colorectal cancer.Ann Intern Med. 2000 Oct 17;133(8):573-84. doi: 10.7326/0003-4819-133-8-200010170-00007. Ann Intern Med. 2000. PMID: 11033584
-
Effect of workup strategy on the cost-effectiveness of fecal occult blood screening for colorectal cancer.Gastroenterology. 1987 Aug;93(2):301-10. doi: 10.1016/0016-5085(87)91019-5. Gastroenterology. 1987. PMID: 3109993
-
Screening for colorectal cancer.Ann Intern Med. 1990 Sep 1;113(5):373-84. doi: 10.7326/0003-4819-113-5-373. Ann Intern Med. 1990. PMID: 2200321 Review.
-
Cost effectiveness of HemoQuant versus Hemoccult for colorectal cancer screening.J Gen Intern Med. 1988 Mar-Apr;3(2):132-8. doi: 10.1007/BF02596117. J Gen Intern Med. 1988. PMID: 3128650
-
[Screening for colorectal neoplasms. A review and recommendations].Ugeskr Laeger. 1993 Oct 11;155(41):3272-7. Ugeskr Laeger. 1993. PMID: 8256320 Review. Danish.
Cited by
-
Screening for colorectal cancer.Ulster Med J. 1997 May;66(1):1-8. Ulster Med J. 1997. PMID: 9185482 Free PMC article. Review.
-
Estimating the Effect of Targeted Screening Strategies: An Application to Colonoscopy and Colorectal Cancer.Epidemiology. 2017 Jul;28(4):470-478. doi: 10.1097/EDE.0000000000000668. Epidemiology. 2017. PMID: 28368944 Free PMC article. Review.
-
Follow-up after colorectal polypectomy: a benefit-risk analysis of German surveillance recommendations.Int J Colorectal Dis. 2007 Aug;22(8):929-39. doi: 10.1007/s00384-006-0252-0. Epub 2007 Feb 6. Int J Colorectal Dis. 2007. PMID: 17279350
-
Guidance on large bowel surveillance for people with two first degree relatives with colorectal cancer or one first degree relative diagnosed with colorectal cancer under 45 years.Gut. 2002 Oct;51 Suppl 5(Suppl 5):V17-20. doi: 10.1136/gut.51.suppl_5.v17. Gut. 2002. PMID: 12221035 Free PMC article. No abstract available.
-
Prevention, screening and treatment of colorectal cancer: a global and regional generalized cost effectiveness analysis.Cost Eff Resour Alloc. 2010 Mar 17;8:2. doi: 10.1186/1478-7547-8-2. Cost Eff Resour Alloc. 2010. PMID: 20236531 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources